Effect of Combination Therapy of Ezetimibe and Rosuvastatin on Regression of Coronary Atherosclerosis in Patients With Coronary Artery Disease

Masuda, Jun; Tsuruo, Takashi; Yamada, Tomomi; Nishimura, Yuki; Sasou, Takashi; Nakata, Takashi; Sawai, Terumitsu; Fujimoto, Naoki; Dohi, Kaoru; Miyahara, Masaya; Nishikawa, Masakatsu; Nakamura, Mashio; M, Ito

doi:10.1536/ihj.14-311

Cited by 53 publications

(44 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the natural course of heterozygous FH patients, around 50% of men experienced adverse cardiac events by the age of 50 years and 30% of females by the age of 60 years. 4) Nevertheless, it is necessary to perform more appropriate diagnosis and intensive cholesterol-lowering therapy to prevent the development of premature CAD, 8) the majority of patients with FH are either underdiagnosed or undertreated.…”

mentioning

confidence: 99%

Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome

et al. 2017

View full text Add to dashboard Cite

SummaryHeterozygous familial hypercholesterolemia (FH) represents a strong risk for development of premature coronary artery disease (CAD). However, the majority of patients with FH are undiagnosed and the prevalence likely represents an underestimate in most countries. In Japan, the possible contribution of FH to the development of CAD may be higher because of the low incidence of CAD among the general population. We estimated the prevalence of heterozygous FH by measuring Achilles tendon thickness (ATT) in patients with acute coronary syndrome (ACS).A total of 359 patients suffering from ACS were enrolled in this multicenter registration study. Heterozygous FH was defined according to the diagnostic criteria proposed by the Japan Atherosclerosis Society. After excluding 63 patients because of missing ATT data or plasma triglyceride levels that were 4.5 mmol/L or more, 296 patients were eligible for inclusion in the study. The number of patients with ATT of 9 mm or more was 53 (17.9%). They were significantly younger and had significantly higher LDL cholesterol levels than patients with an ATT less than 9 mm. The prevalence of heterozygous FH was 5.7% (1/17.5) and more prominent in younger patients who were less than 60 years old (7.8%). In patients with ATT of 9 mm or more, approximately 1 in 3.5 fulfilled the criteria for heterozygous FH.We demonstrated the usefulness of measuring ATT by radiography and the high prevalence of heterozygous FH in patients with ACS in Japan, especially in younger patients who were less than 60 years old. (Int Heart J 2017; 58: 88-94)

show abstract

mentioning

confidence: 99%

Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome

et al. 2017

View full text Add to dashboard Cite

show abstract

“…There were no significant differences in percentage changes of LDL-C levels from baseline to follow-up between the atorvastatin and rosuvastatin groups. Highdensity lipoprotein-cholesterol seemed to be higher at follow-up than at baseline (46.8 ± 12.4 mg/dL to 51.3 ± 14.4 mg/dL and 45.7 ± 9.3 mg/dL to 49.5 ± 7.9 mg/dL for atorvastatin and rosuvastatin groups, respectively), but Ishikawa, ET AL 3 ) 33.8 ± 20.0 29.6 ± 13.6 0.47 Lipid pool (mm 3 ) 36.0 ± 19.5 34.9 ± 20.4 0.87 these differences were not significant (Table II).…”

Section: Methodsmentioning

confidence: 91%

“…17) The area of each tissue characterization (mm 2 ) was obtained from the multiplication of plaque CSA and the % tissue characterization volume; we assumed its volume (mm 3 ) per 1 mm in length and found the volume (mm 3 ) of the sum that traced and calculated each organizational area. Changes in these volumes were compared between atorvastatin and rosuvastatin groups.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome

et al. 2018

View full text Add to dashboard Cite

SummaryStatins can be differentiated into two types, based on their solubility, which have potentially differing effects on the coronary artery wall. However, suspected differences in statins' effects on plaque composition have not been systemically investigated.Sixty-seven patients with acute coronary syndrome (ACS) were randomly assigned to either atorvastatin (10 mg/day) or rosuvastatin (2.5 mg/day). Intravascular ultrasound (IVUS) and integrated backscatter (IB)-IVUS, an established tool to quantify each plaque's components, were performed immediately after emergent percutaneous coronary intervention (PCI). Follow-up IVUS was performed between 6 and 12 months after PCI. Serial changes in serum lipid profiles and plaque composition volumes were compared between the two groups.Thirty-five patients were eligible for serial IB-IVUS analyses. The mean low-density lipoprotein-cholesterol level significantly decreased in the atorvastatin and rosuvastatin groups (P < 0.001); plaque volumes were also significantly reduced from 82.0 ± 46.2 to 74.9 ± 41.3 mm 3 (P = 0.01) and from 74.7 ± 35.3 to 67.7 ± 27.0 mm 3 (P = 0.02), respectively. IB-IVUS revealed a significant reduction in fibrous volume from 33.8 ± 20.0 to 27.5 ± 14.9 mm 3 (P < 0.01) and from 29.6 ± 13.6 to 24.8 ± 7.6 mm 3 (P < 0.05), respectively; however, significant changes were not noted in the volume of the lipid pool for the atorvastatin group and the rosuvastatin group, respectively.Water-and lipid-soluble statins may be similarly effective in reducing coronary plaques in patients with ACS as judged qualitatively and quantitatively. Further study is needed to determine whether differences between water-and lipid-soluble statins affect plaque components.(Int Heart J 2018; 59: 27-34)

show abstract

“…Ezetimibe reduces the absorption of cholesterol from the intestine and cause extra LDL-C reduction when added to statin (30). Previous studies have shown that ezetimibe either used alone or with statin decreases secretory phospholipase A2 activity and possibly regress carotid or coronary plaque burdens (31)(32)(33). Clinical comparisons between ezetimibe-simvastatin and simvastatin in patients with ACS have been conducted in the IMPROVE-IT study.…”

Section: Discussionmentioning

confidence: 99%

Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients

Liu

Chen

Lin

et al. 2016

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

show abstract

Effect of Combination Therapy of Ezetimibe and Rosuvastatin on Regression of Coronary Atherosclerosis in Patients With Coronary Artery Disease

Cited by 53 publications

References 35 publications

Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome

Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome

Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome

Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients

Contact Info

Product

Resources

About